We are live on ! Find out more
MBX

MBX Biosciences
MBX

79 hedge funds and large institutions have $263M invested in MBX Biosciences in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 10

60% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 15

25% more funds holding

Funds holding: 63 → 79 (+16)

8.15% more ownership

Funds ownership: 98.57% → 106.72% (+8.2%)

57% less capital invested

Capital invested by funds: $606M → $263M (-$343M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
79
Holders Change
+16
Holders Change %
+25.4%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
26
Increased
24
Reduced
15
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$12M
2
WP
Woodline Partners
California
+$2.84M
3
OM
Opaleye Management
Massachusetts
+$2.64M
4
JP Morgan Chase
JP Morgan Chase
New York
+$2.03M
5
O
OrbiMed
New York
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.06M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.22M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.87M
4
Millennium Management
Millennium Management
New York
-$1.73M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$641K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$1.26M -$1.73M -163,202 -49%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$1.12M +$1.21M +114,904 +314%
EAM
28
Exome Asset Management
New York
$982K +$1.41M +133,113 New
Morgan Stanley
29
Morgan Stanley
New York
$846K +$960K +90,775 +381%
Marshall Wace
30
Marshall Wace
United Kingdom
$821K +$902K +85,311 +329%
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$815K +$1.17M +110,482 New
Citigroup
32
Citigroup
New York
$718K +$935K +88,464 +998%
SC
33
Stempoint Capital
New York
$713K +$1.02M +96,615 New
Northern Trust
34
Northern Trust
Illinois
$712K +$61.6K +5,825 +6%
Charles Schwab
35
Charles Schwab
California
$698K +$13.1K +1,235 +1%
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$370K +$4.6K +435 +0.9%
AWA
37
Aaron Wealth Advisors
Illinois
$369K +$529K +50,000 New
SC
38
Shay Capital
New York
$363K +$519K +49,133 New
Fidelity Investments
39
Fidelity Investments
Massachusetts
$326K +$208K +19,667 +80%
PCM
40
Prelude Capital Management
New York
$297K +$425K +40,225 New
Two Sigma Investments
41
Two Sigma Investments
New York
$250K +$358K +33,833 New
Walleye Capital
42
Walleye Capital
New York
$240K +$344K +32,490 New
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$228K +$311K +29,430 +1,980%
JF
44
Jump Financial
Illinois
$214K +$307K +28,996 New
Bank of America
45
Bank of America
North Carolina
$207K +$127K +12,031 +75%
UBS Group
46
UBS Group
Switzerland
$203K -$195K -18,402 -40%
AA
47
ALPS Advisors
Colorado
$192K -$10.4K -986 -4%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$176K -$42 -4 -0%
Squarepoint
49
Squarepoint
New York
$148K +$213K +20,098 New
Verition Fund Management
50
Verition Fund Management
Connecticut
$146K +$210K +19,815 New
1
2
3 4

MBX Hedge Fund Activity: Q1 2025 in Review

79 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q1 2025, worth a combined $263M — down 57% from $606M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new MBX positions and 10 closed out — a net gain of 16 holders — while 24 added to existing stakes and 15 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $12M. The largest seller was Citadel Advisors, exiting entirely with an estimated $4.06M sold.

  • 79 institutional investors held MBX Biosciences (MBX) as of Q1 2025, up from 63 in Q4 2024.
  • Funds reported $263M of MBX Biosciences stock for Q1 2025, down 57% quarter-over-quarter.
  • 26 funds opened new MBX Biosciences positions in Q1 2025 and 10 closed out, a net change of +16 holders.
  • The largest MBX Biosciences buyer in Q1 2025 was MPM BioImpact, an estimated $12M added.
  • The largest MBX Biosciences seller in Q1 2025 was Citadel Advisors, an estimated $4.06M sold.

Based on aggregated 13F filings for Q1 2025.